We’re gearing up for #SITC2025! We will share the latest research on our lead investigative cell therapy intended for mCRPC, CAR T cell therapy design, and our foundation model predicting targets for overcoming T cell exhaustion. Join us Nov 7–9: bit.ly/3JHY0wb @sitcancer.bsky.social #CellTherapy

We’re presenting at the CAR-TCR Summit tomorrow on the development of our T cell therapy intended for metastatic prostate cancer and maintaining high potency in our development of cell therapy products. https://bit.ly/3KBpuDJ #CellTherapy #CancerResearch #ProstateCancer

We’re developing a CAR-T cell therapy as a potential treatment for metastatic prostate cancer, for which new and more effective treatments are urgently needed. Stay tuned as we advance this program toward the clinic. More: https://bit.ly/3VqLxzg #ProstateCancer #CancerResearch #biosky #oncsky

Join ArsenalBio scientist Sophia Phillips on July 17 at the Process Development for Cell Therapies Summit for a case study on overcoming process development challenges in solid tumor-targeting cell therapies. Learn more at: bit.ly/3IuKGdF #CellTherapy #DrugDevelopment #biosky

Hello, Bluesky! 👋 We’re ArsenalBio, a programmable, clinical-stage cell therapy company with one clear purpose: defeat cancer. Follow us to explore the future of solid tumor therapies, cutting-edge CRISPR tech, and how we’re Engineering Hope™ for patients everywhere.